Radionuclide spatial distribution and dose deposition for in vitro assessments of 212 Pb-αVCAM-1 targeted alpha therapy

Targeted alpha therapy (TAT) takes advantage of the short-range and high-linear energy transfer of α-particles and is increasingly used, especially for the treatment of metastatic lesions. Nevertheless, dosimetry of α-emitters is challenging for the very same reasons, even for in vitro experiments....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medical physics (Lancaster) 2020-03, Vol.47 (3), p.1317-1326
Hauptverfasser: Frelin-Labalme, Anne-Marie, Roger, Thomas, Falzone, Nadia, Quan Lee, Boon, Sibson, Nicola R, Vallis, Katherine A, Bernaudin, Myriam, Valable, Samuel, Corroyer-Dulmont, Aurélien
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1326
container_issue 3
container_start_page 1317
container_title Medical physics (Lancaster)
container_volume 47
creator Frelin-Labalme, Anne-Marie
Roger, Thomas
Falzone, Nadia
Quan Lee, Boon
Sibson, Nicola R
Vallis, Katherine A
Bernaudin, Myriam
Valable, Samuel
Corroyer-Dulmont, Aurélien
description Targeted alpha therapy (TAT) takes advantage of the short-range and high-linear energy transfer of α-particles and is increasingly used, especially for the treatment of metastatic lesions. Nevertheless, dosimetry of α-emitters is challenging for the very same reasons, even for in vitro experiments. Assumptions, such as the uniformity of the distribution of radionuclides in the culture medium, are commonly made, which could have a profound impact on dose calculations. In this study we measured the spatial distribution of α-emitting Pb coupled to an anti-VCAM-1 antibody ( Pb-αVCAM-1) and its evolution over time in the context of in vitro irradiations. Two experimental setups were implemented without cells to measure α-particle count rates and energy spectra in culture medium containing 15 kBq of Pb-α-VCAM-1. Silicon detectors were placed above and below cell culture dishes for 20 h. One of the dishes had a 2.5-µm-thick mylar-base allowing easy detection of the α-particles. Monte Carlo simulations were performed to analyze experimental spectra. Experimental setups were modeled and α-energy spectra were simulated in the silicon detectors for different decay positions in the culture medium. Simulated spectra were then used to deconvolute experimental spectra to determine the spatial distribution of Pb-αVCAM-1 in the medium. This distribution was finally used to calculate the dose deposition in cell culture experiments. Experimental count rates and energy spectra showed differences in measurements taken at the top and the bottom of dishes and temporal variations that did not follow Pb decay. The radionuclide spatial distribution was shown to be composed of a uniform distribution and concentration gradients at the top and the bottom, which were subjected to temporal variations that may be explained by gravity and electrostatic attraction. The absorbed dose in cells calculated from this distribution was compared with the dose expected for a uniform and static distribution and found to be 1.75 times higher, which is highly significant to interpret biological observations. This study demonstrated that accurate dosimetry of α-emitters requires the experimental determination of radionuclide spatial and temporal distribution and highlighted that in vitro assessment of dose for TAT cannot only rely on a uniform distribution of activity in the culture medium. The reliability and reproducibility of future experiments should benefit from specifically developed dosimetry to
doi_str_mv 10.1002/mp.13969
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_mp_13969</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>31838744</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1284-3c81de76644592ee9bcbcb88c0d0db901427f7da904ca88ec79ac95cebdd23ac3</originalsourceid><addsrcrecordid>eNo9kMtKAzEUhoMotlbBJ5As3Uw9ucxMsizFG1QUUbdDJsnYyFxCkop9LF_EZ7K2Kmfxw_k__sWH0CmBKQGgF52fEiYLuYfGlJcs4xTkPhoDSJ5RDvkIHcX4BgAFy-EQjRgRTJScj9HHozJu6Fe6dcbi6FVyqsXGxRRcvUqbCqveYDNEi431Q3TbXzME7Hr87lIYsIrRxtjZPkU8NJgSih_q7OvzZT67ywhOKrzaZA1WrV8qnJY2KL8-RgeNaqM9-c0Jer66fJrfZIv769v5bJFpQgXPmBbE2LIoOM8ltVbWenNCaDBgagmE07IpjZLAtRLC6lIqLXNta2MoU5pN0PluV4chxmCbygfXqbCuCFQ_8qrOV1t5G_Rsh_pV3VnzD_7ZYt-sgGyQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Radionuclide spatial distribution and dose deposition for in vitro assessments of 212 Pb-αVCAM-1 targeted alpha therapy</title><source>MEDLINE</source><source>Wiley Journals</source><source>Alma/SFX Local Collection</source><creator>Frelin-Labalme, Anne-Marie ; Roger, Thomas ; Falzone, Nadia ; Quan Lee, Boon ; Sibson, Nicola R ; Vallis, Katherine A ; Bernaudin, Myriam ; Valable, Samuel ; Corroyer-Dulmont, Aurélien</creator><creatorcontrib>Frelin-Labalme, Anne-Marie ; Roger, Thomas ; Falzone, Nadia ; Quan Lee, Boon ; Sibson, Nicola R ; Vallis, Katherine A ; Bernaudin, Myriam ; Valable, Samuel ; Corroyer-Dulmont, Aurélien</creatorcontrib><description>Targeted alpha therapy (TAT) takes advantage of the short-range and high-linear energy transfer of α-particles and is increasingly used, especially for the treatment of metastatic lesions. Nevertheless, dosimetry of α-emitters is challenging for the very same reasons, even for in vitro experiments. Assumptions, such as the uniformity of the distribution of radionuclides in the culture medium, are commonly made, which could have a profound impact on dose calculations. In this study we measured the spatial distribution of α-emitting Pb coupled to an anti-VCAM-1 antibody ( Pb-αVCAM-1) and its evolution over time in the context of in vitro irradiations. Two experimental setups were implemented without cells to measure α-particle count rates and energy spectra in culture medium containing 15 kBq of Pb-α-VCAM-1. Silicon detectors were placed above and below cell culture dishes for 20 h. One of the dishes had a 2.5-µm-thick mylar-base allowing easy detection of the α-particles. Monte Carlo simulations were performed to analyze experimental spectra. Experimental setups were modeled and α-energy spectra were simulated in the silicon detectors for different decay positions in the culture medium. Simulated spectra were then used to deconvolute experimental spectra to determine the spatial distribution of Pb-αVCAM-1 in the medium. This distribution was finally used to calculate the dose deposition in cell culture experiments. Experimental count rates and energy spectra showed differences in measurements taken at the top and the bottom of dishes and temporal variations that did not follow Pb decay. The radionuclide spatial distribution was shown to be composed of a uniform distribution and concentration gradients at the top and the bottom, which were subjected to temporal variations that may be explained by gravity and electrostatic attraction. The absorbed dose in cells calculated from this distribution was compared with the dose expected for a uniform and static distribution and found to be 1.75 times higher, which is highly significant to interpret biological observations. This study demonstrated that accurate dosimetry of α-emitters requires the experimental determination of radionuclide spatial and temporal distribution and highlighted that in vitro assessment of dose for TAT cannot only rely on a uniform distribution of activity in the culture medium. The reliability and reproducibility of future experiments should benefit from specifically developed dosimetry tools and methods.</description><identifier>ISSN: 0094-2405</identifier><identifier>EISSN: 2473-4209</identifier><identifier>DOI: 10.1002/mp.13969</identifier><identifier>PMID: 31838744</identifier><language>eng</language><publisher>United States</publisher><subject>Alpha Particles - therapeutic use ; Immunoconjugates - immunology ; Immunoconjugates - therapeutic use ; Lead Radioisotopes - therapeutic use ; Monte Carlo Method ; Radiation Dosage ; Radiotherapy Dosage ; Vascular Cell Adhesion Molecule-1 - immunology</subject><ispartof>Medical physics (Lancaster), 2020-03, Vol.47 (3), p.1317-1326</ispartof><rights>2019 American Association of Physicists in Medicine.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1284-3c81de76644592ee9bcbcb88c0d0db901427f7da904ca88ec79ac95cebdd23ac3</citedby><cites>FETCH-LOGICAL-c1284-3c81de76644592ee9bcbcb88c0d0db901427f7da904ca88ec79ac95cebdd23ac3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31838744$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Frelin-Labalme, Anne-Marie</creatorcontrib><creatorcontrib>Roger, Thomas</creatorcontrib><creatorcontrib>Falzone, Nadia</creatorcontrib><creatorcontrib>Quan Lee, Boon</creatorcontrib><creatorcontrib>Sibson, Nicola R</creatorcontrib><creatorcontrib>Vallis, Katherine A</creatorcontrib><creatorcontrib>Bernaudin, Myriam</creatorcontrib><creatorcontrib>Valable, Samuel</creatorcontrib><creatorcontrib>Corroyer-Dulmont, Aurélien</creatorcontrib><title>Radionuclide spatial distribution and dose deposition for in vitro assessments of 212 Pb-αVCAM-1 targeted alpha therapy</title><title>Medical physics (Lancaster)</title><addtitle>Med Phys</addtitle><description>Targeted alpha therapy (TAT) takes advantage of the short-range and high-linear energy transfer of α-particles and is increasingly used, especially for the treatment of metastatic lesions. Nevertheless, dosimetry of α-emitters is challenging for the very same reasons, even for in vitro experiments. Assumptions, such as the uniformity of the distribution of radionuclides in the culture medium, are commonly made, which could have a profound impact on dose calculations. In this study we measured the spatial distribution of α-emitting Pb coupled to an anti-VCAM-1 antibody ( Pb-αVCAM-1) and its evolution over time in the context of in vitro irradiations. Two experimental setups were implemented without cells to measure α-particle count rates and energy spectra in culture medium containing 15 kBq of Pb-α-VCAM-1. Silicon detectors were placed above and below cell culture dishes for 20 h. One of the dishes had a 2.5-µm-thick mylar-base allowing easy detection of the α-particles. Monte Carlo simulations were performed to analyze experimental spectra. Experimental setups were modeled and α-energy spectra were simulated in the silicon detectors for different decay positions in the culture medium. Simulated spectra were then used to deconvolute experimental spectra to determine the spatial distribution of Pb-αVCAM-1 in the medium. This distribution was finally used to calculate the dose deposition in cell culture experiments. Experimental count rates and energy spectra showed differences in measurements taken at the top and the bottom of dishes and temporal variations that did not follow Pb decay. The radionuclide spatial distribution was shown to be composed of a uniform distribution and concentration gradients at the top and the bottom, which were subjected to temporal variations that may be explained by gravity and electrostatic attraction. The absorbed dose in cells calculated from this distribution was compared with the dose expected for a uniform and static distribution and found to be 1.75 times higher, which is highly significant to interpret biological observations. This study demonstrated that accurate dosimetry of α-emitters requires the experimental determination of radionuclide spatial and temporal distribution and highlighted that in vitro assessment of dose for TAT cannot only rely on a uniform distribution of activity in the culture medium. The reliability and reproducibility of future experiments should benefit from specifically developed dosimetry tools and methods.</description><subject>Alpha Particles - therapeutic use</subject><subject>Immunoconjugates - immunology</subject><subject>Immunoconjugates - therapeutic use</subject><subject>Lead Radioisotopes - therapeutic use</subject><subject>Monte Carlo Method</subject><subject>Radiation Dosage</subject><subject>Radiotherapy Dosage</subject><subject>Vascular Cell Adhesion Molecule-1 - immunology</subject><issn>0094-2405</issn><issn>2473-4209</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kMtKAzEUhoMotlbBJ5As3Uw9ucxMsizFG1QUUbdDJsnYyFxCkop9LF_EZ7K2Kmfxw_k__sWH0CmBKQGgF52fEiYLuYfGlJcs4xTkPhoDSJ5RDvkIHcX4BgAFy-EQjRgRTJScj9HHozJu6Fe6dcbi6FVyqsXGxRRcvUqbCqveYDNEi431Q3TbXzME7Hr87lIYsIrRxtjZPkU8NJgSih_q7OvzZT67ywhOKrzaZA1WrV8qnJY2KL8-RgeNaqM9-c0Jer66fJrfZIv769v5bJFpQgXPmBbE2LIoOM8ltVbWenNCaDBgagmE07IpjZLAtRLC6lIqLXNta2MoU5pN0PluV4chxmCbygfXqbCuCFQ_8qrOV1t5G_Rsh_pV3VnzD_7ZYt-sgGyQ</recordid><startdate>202003</startdate><enddate>202003</enddate><creator>Frelin-Labalme, Anne-Marie</creator><creator>Roger, Thomas</creator><creator>Falzone, Nadia</creator><creator>Quan Lee, Boon</creator><creator>Sibson, Nicola R</creator><creator>Vallis, Katherine A</creator><creator>Bernaudin, Myriam</creator><creator>Valable, Samuel</creator><creator>Corroyer-Dulmont, Aurélien</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>202003</creationdate><title>Radionuclide spatial distribution and dose deposition for in vitro assessments of 212 Pb-αVCAM-1 targeted alpha therapy</title><author>Frelin-Labalme, Anne-Marie ; Roger, Thomas ; Falzone, Nadia ; Quan Lee, Boon ; Sibson, Nicola R ; Vallis, Katherine A ; Bernaudin, Myriam ; Valable, Samuel ; Corroyer-Dulmont, Aurélien</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1284-3c81de76644592ee9bcbcb88c0d0db901427f7da904ca88ec79ac95cebdd23ac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Alpha Particles - therapeutic use</topic><topic>Immunoconjugates - immunology</topic><topic>Immunoconjugates - therapeutic use</topic><topic>Lead Radioisotopes - therapeutic use</topic><topic>Monte Carlo Method</topic><topic>Radiation Dosage</topic><topic>Radiotherapy Dosage</topic><topic>Vascular Cell Adhesion Molecule-1 - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Frelin-Labalme, Anne-Marie</creatorcontrib><creatorcontrib>Roger, Thomas</creatorcontrib><creatorcontrib>Falzone, Nadia</creatorcontrib><creatorcontrib>Quan Lee, Boon</creatorcontrib><creatorcontrib>Sibson, Nicola R</creatorcontrib><creatorcontrib>Vallis, Katherine A</creatorcontrib><creatorcontrib>Bernaudin, Myriam</creatorcontrib><creatorcontrib>Valable, Samuel</creatorcontrib><creatorcontrib>Corroyer-Dulmont, Aurélien</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Medical physics (Lancaster)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Frelin-Labalme, Anne-Marie</au><au>Roger, Thomas</au><au>Falzone, Nadia</au><au>Quan Lee, Boon</au><au>Sibson, Nicola R</au><au>Vallis, Katherine A</au><au>Bernaudin, Myriam</au><au>Valable, Samuel</au><au>Corroyer-Dulmont, Aurélien</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radionuclide spatial distribution and dose deposition for in vitro assessments of 212 Pb-αVCAM-1 targeted alpha therapy</atitle><jtitle>Medical physics (Lancaster)</jtitle><addtitle>Med Phys</addtitle><date>2020-03</date><risdate>2020</risdate><volume>47</volume><issue>3</issue><spage>1317</spage><epage>1326</epage><pages>1317-1326</pages><issn>0094-2405</issn><eissn>2473-4209</eissn><abstract>Targeted alpha therapy (TAT) takes advantage of the short-range and high-linear energy transfer of α-particles and is increasingly used, especially for the treatment of metastatic lesions. Nevertheless, dosimetry of α-emitters is challenging for the very same reasons, even for in vitro experiments. Assumptions, such as the uniformity of the distribution of radionuclides in the culture medium, are commonly made, which could have a profound impact on dose calculations. In this study we measured the spatial distribution of α-emitting Pb coupled to an anti-VCAM-1 antibody ( Pb-αVCAM-1) and its evolution over time in the context of in vitro irradiations. Two experimental setups were implemented without cells to measure α-particle count rates and energy spectra in culture medium containing 15 kBq of Pb-α-VCAM-1. Silicon detectors were placed above and below cell culture dishes for 20 h. One of the dishes had a 2.5-µm-thick mylar-base allowing easy detection of the α-particles. Monte Carlo simulations were performed to analyze experimental spectra. Experimental setups were modeled and α-energy spectra were simulated in the silicon detectors for different decay positions in the culture medium. Simulated spectra were then used to deconvolute experimental spectra to determine the spatial distribution of Pb-αVCAM-1 in the medium. This distribution was finally used to calculate the dose deposition in cell culture experiments. Experimental count rates and energy spectra showed differences in measurements taken at the top and the bottom of dishes and temporal variations that did not follow Pb decay. The radionuclide spatial distribution was shown to be composed of a uniform distribution and concentration gradients at the top and the bottom, which were subjected to temporal variations that may be explained by gravity and electrostatic attraction. The absorbed dose in cells calculated from this distribution was compared with the dose expected for a uniform and static distribution and found to be 1.75 times higher, which is highly significant to interpret biological observations. This study demonstrated that accurate dosimetry of α-emitters requires the experimental determination of radionuclide spatial and temporal distribution and highlighted that in vitro assessment of dose for TAT cannot only rely on a uniform distribution of activity in the culture medium. The reliability and reproducibility of future experiments should benefit from specifically developed dosimetry tools and methods.</abstract><cop>United States</cop><pmid>31838744</pmid><doi>10.1002/mp.13969</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0094-2405
ispartof Medical physics (Lancaster), 2020-03, Vol.47 (3), p.1317-1326
issn 0094-2405
2473-4209
language eng
recordid cdi_crossref_primary_10_1002_mp_13969
source MEDLINE; Wiley Journals; Alma/SFX Local Collection
subjects Alpha Particles - therapeutic use
Immunoconjugates - immunology
Immunoconjugates - therapeutic use
Lead Radioisotopes - therapeutic use
Monte Carlo Method
Radiation Dosage
Radiotherapy Dosage
Vascular Cell Adhesion Molecule-1 - immunology
title Radionuclide spatial distribution and dose deposition for in vitro assessments of 212 Pb-αVCAM-1 targeted alpha therapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T00%3A25%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radionuclide%20spatial%20distribution%20and%20dose%20deposition%20for%20in%20vitro%20assessments%20of%20212%20Pb-%CE%B1VCAM-1%20targeted%20alpha%20therapy&rft.jtitle=Medical%20physics%20(Lancaster)&rft.au=Frelin-Labalme,%20Anne-Marie&rft.date=2020-03&rft.volume=47&rft.issue=3&rft.spage=1317&rft.epage=1326&rft.pages=1317-1326&rft.issn=0094-2405&rft.eissn=2473-4209&rft_id=info:doi/10.1002/mp.13969&rft_dat=%3Cpubmed_cross%3E31838744%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31838744&rfr_iscdi=true